Longeveron Sets June 24 Presentation for Laromestrocel, Targets $11B+ Indication Markets
LGVN•Longeveron will present laromestrocel stem cell data for HLHS, Alzheimer’s, Pediatric Dilated Cardiomyopathy and Aging-related Frailty at the BIO International Convention on June 24, targeting markets of $1B, $5B+, $1B and $4B. The company completed Phase 2b ELPIS II enrollment for HLHS with top-line results due in August.
1. BIO International Convention Presentation
Longeveron will host a corporate presentation on June 24 at 2:15pm PT in Theater 4 of the BIO International Convention in San Diego. CEO Stephen Willard, CSO Dr. Joshua Hare and Business Development lead Than Powell will engage with global pharmaceutical executives to explore licensing and partnership opportunities.
2. Laromestrocel Pipeline and Market Potential
The presentation will highlight laromestrocel data across four initial indications: Hypoplastic Left Heart Syndrome, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy and Aging-related Frailty. Longeveron estimates these markets at approximately $1 billion, $5+ billion, $1 billion and up to $4 billion respectively, underscoring broad commercial potential.
3. Clinical Trial Progress
Laromestrocel has shown positive initial results in five clinical trials spanning three indications, including Phase 1 & 2 studies in Alzheimer’s and Aging-related Frailty and Phase 1 in HLHS. The company has completed enrollment for the Phase 2b ELPIS II trial in HLHS, with top-line data expected in August 2026.
4. Strategic Partnerships and Intellectual Property
Longeveron plans a robust partnering strategy to accelerate development timelines and leverage larger organizations’ resources for its four programs. The laromestrocel platform is protected by a global portfolio of 52 patents covering composition of matter, methods of use and manufacturing processes, creating a competitive moat.
